➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Dow
Baxter
Harvard Business School
Medtronic
Mallinckrodt

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

Claims for Patent: 7,863,501

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,863,501
Title:B-type gene from oil palm
Abstract: The present invention relates generally to genetic sequences and their complementary forms capable of facilitating the modification of a phenotype of a plant. More particularly, the present invention relates to polynucleotide sequences defining B-type genes, to the proteins encoded thereby, to methods for isolating such polynucleotides and to nucleic acid constructs for the expression thereof. The present invention further provides cells, particularly transformed bacterial or plant cells and to differentiated tissue including whole plants and their progeny comprising cells which contain these nucleic acid constructs or parts of the constructs. Plants and parts of plants, such as flowering and reproductive parts including seeds, also form part of the present invention. The genetic sequences of the present invention may be used inter alia for the production of plants and, in particular, oil palm plants, which have modified phenotypes and/or which exhibits more highly desired characteristics such as, for example, male sterility or plants in which the sex ratio may be manipulated, and for the diagnosis and, preferably, elimination of the mantled phenotype.
Inventor(s): Van Der Linden; Cornelis Gerardus (Bennekom, NL), Alwee; Sharifah Shahrul Rabiah Syed (Selangor, MY), Smulders; Marinus Johannes Maria (Ka Ugchelen, NL), Choo; Cheah Suan (Selangor, MY), Abdullah; Meilina Ong Bt. (Selangor, MY), Eng; Ooi Siew (Selangor, MY)
Assignee: Malaysian Palm Oil Board (Selangor, MY)
Application Number:11/243,296
Patent Claims:1. An isolated nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding a B-type MADS box-type transcription factor or a homolog thereof, wherein said nucleic acid molecule comprises the nucleic acid sequence as set forth in SEQ ID NO: 1 or a nucleic acid sequence having about 95% or more sequence identity to SEQ ID NO: 1 after optimal alignment wherein when said nucleic acid molecule is transformed into a B-type mutant of Arabidopsis, the nucleic acid molecule complements the mutant phenotype.

2. The isolated nucleic acid molecule of claim 1 wherein the nucleotide sequence encodes the amino acid sequence set forth in SEQ ID NO: 2.

3. The isolated nucleic acid molecule of claim 1 comprising the nucleotide sequence set forth in SEQ ID NO: 1.

4. The isolated nucleic acid molecule of claim 1 further comprising a 5' untranslated region and having the nucleotide sequence set forth in SEQ ID NO: 4.

5. The isolated nucleic acid molecule of claim 1 further comprising a 3' untranslated region and having the nucleotide sequence set forth in SEQ ID NO: 3.

6. The isolated nucleic acid molecule of claim 1 comprising an intron selected from the group consisting of: SEQ ID NO: 5, SEQ ID NO: 6 a nucleotide sequence capable of hybridizing under low stringency conditions to SEQ ID NO: 5 and a nucleotide sequence capable of hybridizing under low stringency conditions to SEQ ID NO: 6.

7. The isolated nucleic acid molecule of claim 1 wherein said nucleic acid is isolated from a plant is of the genus Elaeis.

8. The isolated nucleic acid molecule of claim 7 wherein said plant is of the species Elaeis guineensis or Elaeis oleifera.

9. A vector comprising the nucleic acid molecule of claim 1.

10. The vector of claim 9 wherein the vector is a cloning vector.

11. The vector of claim 9 wherein the vector is an expression vector.

12. The vector according to claim 9 wherein the vector is operable in a prokaryotic cell.

13. The vector according to claim 9 wherein the vector is operable in a eukaryotic cell.

14. The vector of claim 12 wherein the prokaryotic cell is a bacterial cell.

15. The vector of claim 14 wherein the bacterial cell is an E. coli cell.

16. The vector of claim 13 wherein the eukaryotic cell is a fungal cell.

17. The vector of claim 13 wherein the eukaryotic cell is a plant cell.

18. An isolated genetically modified cell comprising the nucleic acid of claim 1.

19. The genetically modified cell of claim 18 wherein the cell is a prokaryotic cell.

20. The genetically modified cell of claim 19 wherein the prokaryotic cell is an E. coli cell.

21. The genetically modified cell of claim 18 wherein the cell is a eukaryotic cell.

22. The genetically modified eukaryotic cell of claim 21 wherein the cell is a fungal cell.

23. The genetically modified eukaryotic cell of claim 21 wherein the cell is a plant cell.

24. The genetically modified plant cell of claim 23 wherein the plant cell is an Elaeis sp. cell.

25. The genetically modified plant cell of claim 23 wherein the plant cell is an Arabidopsis sp, cell.

26. A plant tissue culture comprising one or more plant cells according to claim 23.

27. A method of making a modified oil palm plant, comprising expressing the polynucleotide according to claim 1 in the oil palm plant to be modified.

Details for Patent 7,863,501

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Malaysian Palm Oil Board (Selangor, MY) 2024-09-30 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Malaysian Palm Oil Board (Selangor, MY) 2024-09-30 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Malaysian Palm Oil Board (Selangor, MY) 2024-09-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Express Scripts
Baxter
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.